Cansu Karakas1, Ashleigh M Francis2, Min Jin Ha3, Hannah F Wingate2, Richard A Meena2, Min Yi2, Komal S Rasaputra2, Angelica M Gutierrez Barrera4, Banu Arun4, Kim-Anh Do3, Aysegul Sahin5, Khandan Keyomarsi1, Kelly K Hunt1,2. 1. Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 2. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX. 4. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 5. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract
BACKGROUND: Pathologic complete response (pCR) has been shown to be associated with favorable outcomes in breast cancer. Predictors of pCR could be useful in guiding treatment decisions regarding neoadjuvant therapy. The objective of this study was to evaluate cyclin E as a predictor of response to neoadjuvant chemotherapy in breast cancer. METHODS: Patients (n = 285) with stage II-III breast cancer were enrolled in a prospective study and received neoadjuvant chemotherapy with anthracyclines, taxanes, or combination of the two. Pretreatment biopsies from 190 patients and surgical specimens following chemotherapy from 192 patients were available for immunohistochemical analysis. Clinical and pathologic responses were recorded and associated with presence of tumor infiltrating lymphocytes, cyclin E, adipophilin, programmed cell death-ligand 1, and elastase staining and other patient, tumor and treatment characteristics. RESULTS: The pCR rate was significantly lower in patients with cytoplasmic cyclin E staining compared with those who had no cyclin E expression (16.1% vs 38.9%, P = 0.0005). In multivariable logistic regression analysis, the odds of pCR for patients who had cytoplasmic negative tumors was 9.35 times (P value < 0.0001) that compared with patients with cytoplasmic positive tumors after adjusting for ER, PR, and HER2 status. Cytoplasmic cyclin E expression also predicts long-term outcome and is associated with reduced disease free, recurrence free, and overall survival rates, independent of increased pretreatment tumor infiltrating lymphocytes. CONCLUSIONS: Cyclin E independently predicted response to neoadjuvant chemotherapy. Hence, its routine immunohistochemical analysis could be used clinically to identify those breast cancer patients expected to have a poor response to anthracycline/taxane-based chemotherapy.
BACKGROUND: Pathologic complete response (pCR) has been shown to be associated with favorable outcomes in breast cancer. Predictors of pCR could be useful in guiding treatment decisions regarding neoadjuvant therapy. The objective of this study was to evaluate cyclin E as a predictor of response to neoadjuvant chemotherapy in breast cancer. METHODS: Patients (n = 285) with stage II-III breast cancer were enrolled in a prospective study and received neoadjuvant chemotherapy with anthracyclines, taxanes, or combination of the two. Pretreatment biopsies from 190 patients and surgical specimens following chemotherapy from 192 patients were available for immunohistochemical analysis. Clinical and pathologic responses were recorded and associated with presence of tumor infiltrating lymphocytes, cyclin E, adipophilin, programmed cell death-ligand 1, and elastase staining and other patient, tumor and treatment characteristics. RESULTS: The pCR rate was significantly lower in patients with cytoplasmic cyclin E staining compared with those who had no cyclin E expression (16.1% vs 38.9%, P = 0.0005). In multivariable logistic regression analysis, the odds of pCR for patients who had cytoplasmic negative tumors was 9.35 times (P value < 0.0001) that compared with patients with cytoplasmic positive tumors after adjusting for ER, PR, and HER2 status. Cytoplasmic cyclin E expression also predicts long-term outcome and is associated with reduced disease free, recurrence free, and overall survival rates, independent of increased pretreatment tumor infiltrating lymphocytes. CONCLUSIONS: Cyclin E independently predicted response to neoadjuvant chemotherapy. Hence, its routine immunohistochemical analysis could be used clinically to identify those breast cancer patients expected to have a poor response to anthracycline/taxane-based chemotherapy.
Authors: Yanyan Lou; Lixia Diao; Edwin Roger Parra Cuentas; Warren L Denning; Limo Chen; You Hong Fan; Lauren A Byers; Jing Wang; Vassiliki A Papadimitrakopoulou; Carmen Behrens; Jaime Canales Rodriguez; Patrick Hwu; Ignacio I Wistuba; John V Heymach; Don L Gibbons Journal: Clin Cancer Res Date: 2016-02-05 Impact factor: 12.531
Authors: Said Akli; Carolyn S Van Pelt; Tuyen Bui; Asha S Multani; Sandy Chang; David Johnson; Susan Tucker; Khandan Keyomarsi Journal: Cancer Res Date: 2007-08-01 Impact factor: 12.701
Authors: Kimberly S Lucenay; Iman Doostan; Cansu Karakas; Tuyen Bui; Zhiyong Ding; Gordon B Mills; Kelly K Hunt; Khandan Keyomarsi Journal: Cancer Res Date: 2016-02-29 Impact factor: 12.701
Authors: Michael O Meyers; Nancy Klauber-Demore; David W Ollila; Keith D Amos; Dominic T Moore; Amy A Drobish; Emily M Burrows; E Claire Dees; Lisa A Carey Journal: Ann Surg Oncol Date: 2011-03-26 Impact factor: 5.344
Authors: Harry D Bear; Stewart Anderson; Roy E Smith; Charles E Geyer; Eleftherios P Mamounas; Bernard Fisher; Ann M Brown; Andre Robidoux; Richard Margolese; Morton S Kahlenberg; Soonmyung Paik; Atilla Soran; D Lawrence Wickerham; Norman Wolmark Journal: J Clin Oncol Date: 2006-04-10 Impact factor: 44.544
Authors: Jack Cuzick; Mitch Dowsett; Silvia Pineda; Christopher Wale; Janine Salter; Emma Quinn; Lila Zabaglo; Elizabeth Mallon; Andrew R Green; Ian O Ellis; Anthony Howell; Aman U Buzdar; John F Forbes Journal: J Clin Oncol Date: 2011-10-11 Impact factor: 44.544